Lutetium Lu 177 dotatate Recruiting Phase 2 / 3 Trials for Neuroendocrine Tumors / Hepatic Metastases Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2 / 3
clinicaltrials.gov IdentifierTitleDrugs
NCT02489604Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors